Interestingly, the level of IL-22 in the serum of MS patients with active disease was higher than in the serum of inactive (p = 0.017) and progressive (p = 0.015) MS patients and, especially, of HC (p = 0.003) (Fig. 1b). This evidence concerns the gene IL22 and myeloid sarcoma.